Literature DB >> 8972021

Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor--influence of the molecular weightof heparin and ionic strength.

J Aznar1, F España, A Estellés, M Royo.   

Abstract

The ability of unfractionated (UF) heparin and low-molecular-weight heparin (LMWH) to potentiate the inhibition of fibrinolytic and coagulation factors by protein C inhibitor (PCI) was studied. Inhibition of activated protein C (APC), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), thrombin, factor Xa (Xa), factor XIa (XIa) and plasma kallikrein (KK) by PCI was found to be dependent on the size of the polysaccharide. In general, maximal stimulation was reached with UF heparin, except in the case of KK. Differences in heparin stimulation were more pronounced for thrombin, APC, uPA, tPA and XIa, whereas inactivation of Xa by PCI was less dependent on the presence of heparin, and kallikrein showed higher potentiation with LMWH than with UF heparin. The second-order rate constants for enzyme inhibition by PCI were strongly dependent on the ionic strength, and, in general, with an ionic strength higher than 0.15 the heparin stimulation of the inhibition reactions was drastically reduced. These results may explain the large discrepancies in the literature on the effect of heparin on the stimulation of enzyme inhibition by PCI. They also show that LMWH is less efficient in stimulating the PCI inhibition of APC, uPA and tPA, which could contribute to the antithrombotic effect of these enzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972021

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

Review 2.  Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders.

Authors:  Elsa P Bianchini; Claire Auditeau; Mahita Razanakolona; Marc Vasse; Delphine Borgel
Journal:  Front Cardiovasc Med       Date:  2021-01-07

Review 3.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.